Indo Us Bio-Tech Limited
Indo Us Bio-Tech Limited engages in the production, processing, packing, and marketing of seeds in India. The company offers vegetable seeds, such as tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, pepper, chilly, sweet pepper, beet root, cow pea, corriander, onion, watermelon, musk melon, and flower seeds; cotton seed… Read more
Indo Us Bio-Tech Limited (INDOUS) - Total Assets
Latest total assets as of September 2025: ₹1.17 Billion INR
Based on the latest financial reports, Indo Us Bio-Tech Limited (INDOUS) holds total assets worth ₹1.17 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Indo Us Bio-Tech Limited - Total Assets Trend (2022–2025)
This chart illustrates how Indo Us Bio-Tech Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Indo Us Bio-Tech Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Indo Us Bio-Tech Limited's total assets of ₹1.17 Billion consist of 88.6% current assets and 11.4% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0.3% |
| Accounts Receivable | ₹157.54 Million | 16.1% |
| Inventory | ₹706.86 Million | 72.2% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹0.00 | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Indo Us Bio-Tech Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Indo Us Bio-Tech Limited's current assets represent 88.6% of total assets in 2025, an increase from 84.2% in 2022.
- Cash Position: Cash and equivalents constituted 0.3% of total assets in 2025, up from 0.1% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is inventory at 72.2% of total assets.
Indo Us Bio-Tech Limited Competitors by Total Assets
Key competitors of Indo Us Bio-Tech Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥6.84 Billion |
|
ADAMA Ltd
SHE:000553
|
China | CN¥49.93 Billion |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥8.43 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
China | CN¥50.97 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥5.17 Billion |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
China | CN¥19.38 Billion |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥19.75 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥9.46 Billion |
Indo Us Bio-Tech Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Indo Us Bio-Tech Limited generates 1.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Indo Us Bio-Tech Limited generates $ 16.63 in net profit.
Indo Us Bio-Tech Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.67 | 5.74 | 3.87 |
| Quick Ratio | 1.58 | 2.52 | 1.13 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹777.54 Million | ₹ 631.05 Million | ₹ 542.29 Million |
Indo Us Bio-Tech Limited - Advanced Valuation Insights
This section examines the relationship between Indo Us Bio-Tech Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 15.9% |
| Total Assets | ₹978.43 Million |
| Market Capitalization | $5.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Indo Us Bio-Tech Limited's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Indo Us Bio-Tech Limited's assets grew by 15.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Indo Us Bio-Tech Limited (2022–2025)
The table below shows the annual total assets of Indo Us Bio-Tech Limited from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹978.43 Million | +15.85% |
| 2024-03-31 | ₹844.56 Million | +21.58% |
| 2023-03-31 | ₹694.65 Million | +24.90% |
| 2022-03-31 | ₹556.16 Million | -- |